Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Antitubercular Agents"" wg kryterium: Temat


Tytuł:
Travel distance to rifampicin-resistant tuberculosis treatment and its impact on loss to follow-up: the importance of continued RR-TB treatment decentralization in South Africa.
Autorzy:
McNabb KC; Johns Hopkins University School of Nursing, 525 N Wolfe St, Baltimore, MD, 21205, USA. .; Johns Hopkins Center for Infectious Disease and Nursing Innovation, Baltimore, MD, USA. .
Bergman AJ; Johns Hopkins University School of Nursing, 525 N Wolfe St, Baltimore, MD, 21205, USA.; Johns Hopkins Center for Infectious Disease and Nursing Innovation, Baltimore, MD, USA.
Patil A; Johns Hopkins Center for Infectious Disease and Nursing Innovation, Baltimore, MD, USA.
Lowensen K; Johns Hopkins Center for Infectious Disease and Nursing Innovation, Baltimore, MD, USA.
Mthimkhulu N; Johns Hopkins Center for Infectious Disease and Nursing Innovation, Port Shepstone, Republic of South Africa.
Budhathoki C; Johns Hopkins University School of Nursing, 525 N Wolfe St, Baltimore, MD, 21205, USA.; Johns Hopkins Center for Infectious Disease and Nursing Innovation, Baltimore, MD, USA.
Perrin N; Johns Hopkins University School of Nursing, 525 N Wolfe St, Baltimore, MD, 21205, USA.
Farley JE; Johns Hopkins University School of Nursing, 525 N Wolfe St, Baltimore, MD, 21205, USA.; Johns Hopkins Center for Infectious Disease and Nursing Innovation, Baltimore, MD, USA.; Johns Hopkins TB Research Advancement Center, Baltimore, MD, USA.
Pokaż więcej
Źródło:
BMC public health [BMC Public Health] 2024 Feb 23; Vol. 24 (1), pp. 578. Date of Electronic Publication: 2024 Feb 23.
Typ publikacji:
Journal Article
MeSH Terms:
Rifampin*
Tuberculosis, Multidrug-Resistant*/drug therapy
Humans ; South Africa/epidemiology ; Retrospective Studies ; Politics ; Antitubercular Agents/therapeutic use
Czasopismo naukowe
Tytuł:
Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial.
Autorzy:
Semitala FC; Makerere University, Department of Medicine, College of Health Sciences, Kampala, Uganda.; Infectious Diseases Research Collaboration, Kampala, Uganda.; Makerere University Joint AIDS Program, Kampala Uganda.
Kadota JL; Center for Tuberculosis, University of California San Francisco, San Francisco, California, United States of America.; Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
Musinguzi A; Infectious Diseases Research Collaboration, Kampala, Uganda.
Welishe F; Infectious Diseases Research Collaboration, Kampala, Uganda.
Nakitende A; Infectious Diseases Research Collaboration, Kampala, Uganda.
Akello L; Infectious Diseases Research Collaboration, Kampala, Uganda.
Kunihira Tinka L; Infectious Diseases Research Collaboration, Kampala, Uganda.
Nakimuli J; Infectious Diseases Research Collaboration, Kampala, Uganda.
Ritar Kasidi J; Infectious Diseases Research Collaboration, Kampala, Uganda.
Bishop O; Infectious Diseases Research Collaboration, Kampala, Uganda.
Nakasendwa S; Department of Epidemiology and Biostatistics, School of Public Health, Makerere University College of Health Sciences, Kampala, Uganda.
Baik Y; Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Patel D; The Better Lab and Department of Surgery, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
Sammann A; The Better Lab and Department of Surgery, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
Nahid P; Center for Tuberculosis, University of California San Francisco, San Francisco, California, United States of America.; Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
Belknap R; Denver Health and Hospital Authority and Division of Infectious Diseases, Department of Medicine, University of Colorado, Denver, Colorado, United States of America.
Kamya MR; Makerere University, Department of Medicine, College of Health Sciences, Kampala, Uganda.; Infectious Diseases Research Collaboration, Kampala, Uganda.
Handley MA; Center for Vulnerable Populations, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, United States of America.
Phillips PP; Center for Tuberculosis, University of California San Francisco, San Francisco, California, United States of America.; Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
Katahoire A; Child Health and Development Center, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.
Berger CA; Center for Tuberculosis, University of California San Francisco, San Francisco, California, United States of America.; Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
Kiwanuka N; Department of Epidemiology and Biostatistics, School of Public Health, Makerere University College of Health Sciences, Kampala, Uganda.
Katamba A; Clinical Epidemiology & Biostatistics Unit, Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.; Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.
Dowdy DW; Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
Cattamanchi A; Center for Tuberculosis, University of California San Francisco, San Francisco, California, United States of America.; Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.; Division of Pulmonary Diseases and Critical Care Medicine, University of California Irvine, Irvine, California, United States of America.
Pokaż więcej
Źródło:
PLoS medicine [PLoS Med] 2024 Feb 20; Vol. 21 (2), pp. e1004356. Date of Electronic Publication: 2024 Feb 20 (Print Publication: 2024).
Typ publikacji:
Randomized Controlled Trial; Journal Article
MeSH Terms:
Tuberculosis*/drug therapy
Tuberculosis*/prevention & control
Latent Tuberculosis*/drug therapy
HIV Infections*/complications
HIV Infections*/drug therapy
Rifampin/*analogs & derivatives
Humans ; Isoniazid/adverse effects ; Antitubercular Agents/adverse effects ; Uganda ; Drug Therapy, Combination
Czasopismo naukowe
Tytuł:
Development and Validation of a UPLC-MS/MS Method for Therapeutic Drug Monitoring, Pharmacokinetic and Stability Studies of First-Line Antituberculosis Drugs in Urine.
Autorzy:
Abouzid M; Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, 3 Rokietnicka Street, 60-806 Poznań, Poland.; Doctoral School, Poznan University of Medical Sciences, 70 Bukowska Street, 60-812 Poznań, Poland.; Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA.
Kosicka-Noworzyń K; Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, 3 Rokietnicka Street, 60-806 Poznań, Poland.; Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA.
Karaźniewicz-Łada M; Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, 3 Rokietnicka Street, 60-806 Poznań, Poland.; Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA.
Rao P; Division of Infectious Diseases and International Health, University of Virginia, 345 Crispell Drive, Charlottesville, VA 22903, USA.
Modi N; Public Health Research Institute, Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ 07013, USA.
Xie YL; Public Health Research Institute, Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ 07013, USA.
Heysell SK; Division of Infectious Diseases and International Health, University of Virginia, 345 Crispell Drive, Charlottesville, VA 22903, USA.
Główka A; Department of Bromatology, Poznan University of Medical Sciences, 3 Rokietnicka Street, 60-806 Poznań, Poland.
Kagan L; Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA.; Center of Excellence for Pharmaceutical Translational Research and Education, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2024 Jan 09; Vol. 29 (2). Date of Electronic Publication: 2024 Jan 09.
Typ publikacji:
Journal Article
MeSH Terms:
Drug Monitoring*
Rifampin*/therapeutic use
Humans ; Chromatography, Liquid ; Liquid Chromatography-Mass Spectrometry ; Tandem Mass Spectrometry ; Antitubercular Agents/therapeutic use ; Ethambutol
Czasopismo naukowe
Tytuł:
TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis.
Autorzy:
Berry C; Médecins sans Frontières, 10 Furnival Street, London, EC4A1AB, UK. .
du Cros P; Médecins sans Frontières, 10 Furnival Street, London, EC4A1AB, UK.; Burnet Institute, 85 Commercial Rd, Melbourne, VIC, 3004, Australia.
Fielding K; London School of Hygiene and Tropical Medicine, Keppel St, London, WC1E 7HT, UK.
Gajewski S; Swiss Tropical and Public Health Institute (affiliated with University of Basel), Kreuzstrasse 2, 4123, Allschwil, Switzerland.
Kazounis E; Médecins sans Frontières, 10 Furnival Street, London, EC4A1AB, UK.
McHugh TD; UCL Centre for Clinical Microbiology, Royal Free Campus, UCL, Rowland Hill Street, NW3 2PF, London, UK.
Merle C; The Special Programme for Research & Training in Tropical Diseases (TDR) World Health Organization, Avenue Appia 20, 1211, 27, Geneva, Switzerland.
Motta I; Médecins sans Frontières, 10 Furnival Street, London, EC4A1AB, UK.
Moore DAJ; TB Centre, London School of Hygiene and Tropical Medicine, Keppel St, London, WC1E 7HT, UK.
Nyang'wa BT; Médecins sans Frontières, Plantage Middenlaan 14, 1018, DD, Amsterdam, The Netherlands.
Pokaż więcej
Źródło:
Trials [Trials] 2022 Jun 13; Vol. 23 (1), pp. 484. Date of Electronic Publication: 2022 Jun 13.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Antitubercular Agents*/pharmacology
Antitubercular Agents*/therapeutic use
Diarylquinolines*/pharmacology
Diarylquinolines*/therapeutic use
Linezolid*/pharmacology
Linezolid*/therapeutic use
Rifampin*/pharmacology
Rifampin*/therapeutic use
Tuberculosis, Multidrug-Resistant*/diagnosis
Tuberculosis, Multidrug-Resistant*/drug therapy
Adolescent ; Adult ; Humans ; Young Adult ; Antibiotics, Antitubercular/pharmacology ; Antibiotics, Antitubercular/therapeutic use ; Pandemics ; Treatment Outcome ; Multicenter Studies as Topic ; Clinical Trials, Phase III as Topic ; Clinical Trials, Phase II as Topic
Czasopismo naukowe
Tytuł:
Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022.
Autorzy:
Carr W; Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC.
Kurbatova E; Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC.
Starks A; Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC.
Goswami N; Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC.
Allen L; Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC.
Winston C; Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC.
Pokaż więcej
Źródło:
MMWR. Morbidity and mortality weekly report [MMWR Morb Mortal Wkly Rep] 2022 Feb 25; Vol. 71 (8), pp. 285-289. Date of Electronic Publication: 2022 Feb 25.
Typ publikacji:
Journal Article; Practice Guideline
MeSH Terms:
Antitubercular Agents/*therapeutic use
Isoniazid/*therapeutic use
Moxifloxacin/*therapeutic use
Pyrazinamide/*therapeutic use
Rifampin/*analogs & derivatives
Tuberculosis, Pulmonary/*drug therapy
Antitubercular Agents/administration & dosage ; Centers for Disease Control and Prevention, U.S. ; Drug Administration Schedule ; Drug Therapy, Combination ; Humans ; Isoniazid/administration & dosage ; Moxifloxacin/administration & dosage ; Pyrazinamide/administration & dosage ; Randomized Controlled Trials as Topic ; Rifampin/administration & dosage ; Rifampin/therapeutic use ; United States
Czasopismo naukowe
Tytuł:
Bedaquiline resistance probability to guide treatment decision making for rifampicin-resistant tuberculosis: insights from a qualitative study.
Autorzy:
Tu PHT; Department of Family Medicine and Population Health, Faculty of Medicine and Health Sciences, University of Antwerp, Doornstraat 331, 2610, Antwerp, Belgium. .
Anlay DZ; Department of Family Medicine and Population Health, Faculty of Medicine and Health Sciences, University of Antwerp, Doornstraat 331, 2610, Antwerp, Belgium.; Department of Community Health Nursing, School of Nursing, College of Medicine and Health Science, University of Gondar, Gondar, Ethiopia.
Dippenaar A; Department of Family Medicine and Population Health, Faculty of Medicine and Health Sciences, University of Antwerp, Doornstraat 331, 2610, Antwerp, Belgium.
Conceição EC; Department of Science and Innovation, National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Loos J; Dean's Office, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
Van Rie A; Department of Family Medicine and Population Health, Faculty of Medicine and Health Sciences, University of Antwerp, Doornstraat 331, 2610, Antwerp, Belgium.
Pokaż więcej
Źródło:
BMC infectious diseases [BMC Infect Dis] 2022 Nov 22; Vol. 22 (1), pp. 876. Date of Electronic Publication: 2022 Nov 22.
Typ publikacji:
Journal Article
MeSH Terms:
Rifampin*/pharmacology
Rifampin*/therapeutic use
Tuberculosis, Multidrug-Resistant*/drug therapy
Humans ; Bayes Theorem ; Antitubercular Agents/adverse effects ; Decision Making
Czasopismo naukowe
Tytuł:
Characterization of rifampicin-resistant Mycobacterium tuberculosis in Khyber Pakhtunkhwa, Pakistan.
Autorzy:
Khan AS; Department of Microbiology, Kohat University of Science and Technology, Kohat, Pakistan.; Provincial Tuberculosis Reference, Laboratory Hayatabad Medical Complex, Peshawar, Pakistan.
Phelan JE; Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.
Khan MT; Institute of Molecular Biology and Biotechnology (IMBB), The University of Lahore. KM, Defense Road, Lahore, 58810, Pakistan.
Ali S; Provincial Tuberculosis Reference, Laboratory Hayatabad Medical Complex, Peshawar, Pakistan.
Qasim M; Department of Microbiology, Kohat University of Science and Technology, Kohat, Pakistan.
Napier G; Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.
Campino S; Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.
Ahmad S; Institute of Basic Medical Science, Khyber Medical University, Peshawar, KP, Pakistan.
Cabral-Marques O; Department of Immunology, Institute of Biomedical Sciences, University of Sao Paulo, São Paulo, SP, Brazil.; Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, SP, Brazil.; Network of Immunity in Infection, Malignancy, and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), São Paulo, Brazil.
Zhang S; Department of Microbiology and Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Rahman H; Department of Microbiology, Abdul Wali Khan University, Mardan, Pakistan.
Wei DQ; State Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, and Joint Laboratory of International Cooperation in Metabolic and Developmental Sciences, Ministry of Education, Shanghai Jiao Tong University, 800 Dongchuan Road, Minhang District, Shanghai, 200240, China.
Clark TG; Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK. .; Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK. .
Khan TA; Institute of Basic Medical Science, Khyber Medical University, Peshawar, KP, Pakistan. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2021 Jul 09; Vol. 11 (1), pp. 14194. Date of Electronic Publication: 2021 Jul 09.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antitubercular Agents/*pharmacology
Mycobacterium tuberculosis/*genetics
Rifampin/*pharmacology
Tuberculosis, Multidrug-Resistant/*microbiology
Antitubercular Agents/therapeutic use ; Bacterial Proteins/genetics ; Catalase/genetics ; DNA-Directed RNA Polymerases/genetics ; Humans ; Models, Molecular ; Mutation/drug effects ; Mycobacterium tuberculosis/drug effects ; Oxidoreductases/genetics ; Pakistan/epidemiology ; Phylogeny ; Rifampin/therapeutic use ; Tuberculosis, Multidrug-Resistant/drug therapy ; Tuberculosis, Multidrug-Resistant/epidemiology
Czasopismo naukowe
Tytuł:
High rate of completion for weekly rifapentine plus isoniazid treatment in Chinese children with latent tuberculosis infection-A single center study.
Autorzy:
Yang H; Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Yang Y; Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Hu ZD; Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Xia L; Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Liu XH; Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Yu X; The Affiliated Infectious Hospital of Soochow University, Soochow University, Suzhou, Jiangsu, China.
Ma JY; Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Li T; Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Lu SH; Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2021 Jun 11; Vol. 16 (6), pp. e0253159. Date of Electronic Publication: 2021 Jun 11 (Print Publication: 2021).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antitubercular Agents/*therapeutic use
Isoniazid/*therapeutic use
Latent Tuberculosis/*drug therapy
Medication Adherence/*statistics & numerical data
Rifampin/*analogs & derivatives
Adolescent ; Antitubercular Agents/administration & dosage ; Antitubercular Agents/adverse effects ; Child ; Child, Preschool ; China ; Drug Administration Schedule ; Drug Therapy, Combination ; Female ; Humans ; Infant ; Isoniazid/administration & dosage ; Isoniazid/adverse effects ; Male ; Rifampin/administration & dosage ; Rifampin/adverse effects ; Rifampin/therapeutic use
Czasopismo naukowe
Tytuł:
Treatment shortening of drug-sensitive pulmonary tuberculosis using high-dose rifampicin for 3 months after culture conversion (Hi-DoRi-3): a study protocol for an open-label randomized clinical trial.
Autorzy:
Kwak N; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.
Jeon D; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, South Korea.
Park Y; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, South Korea.
Kang YA; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, South Korea.
Kim KJ; Department of R&D, Korean Institute of Tuberculosis, Cheongju, South Korea.
Kim YR; Clinical Research Section, International Tuberculosis Research Center, Seoul, South Korea.
Kwon BS; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
Kwon YS; Department of Internal Medicine, Chonnam National University Medical School, Chonnam National University Hospital, Gwangju, South Korea.
Kim HJ; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
Lee JH; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
Lee JY; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, National Medical Center, Seoul, South Korea.
Lee JK; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, South Korea.
Mok J; Division of Pulmonology, Allergy and Critical Care Medicine, Department of Internal Medicine, Pusan National University Hospital, Busan, South Korea.
Cheon M; Medical Research Collaborating Center, Seoul National University Hospital, Seoul, South Korea.
Park J; Medical Research Collaborating Center, Seoul National University Hospital, Seoul, South Korea.
Hahn S; Medical Research Collaborating Center, Seoul National University Hospital, Seoul, South Korea.; Department of Human Systems Medicine, Seoul National University College of Medicine, Seoul, South Korea.
Yim JJ; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea. .
Pokaż więcej
Źródło:
Trials [Trials] 2022 Aug 17; Vol. 23 (1), pp. 666. Date of Electronic Publication: 2022 Aug 17.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Rifampin*/adverse effects
Tuberculosis, Pulmonary*/diagnosis
Tuberculosis, Pulmonary*/drug therapy
Antitubercular Agents/adverse effects ; Drug Therapy, Combination/adverse effects ; Humans ; Isoniazid/adverse effects ; Multicenter Studies as Topic ; Pyrazinamide/adverse effects ; Randomized Controlled Trials as Topic ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Dual antitubercular drug loaded liposomes for macrophage targeting: development, characterisation, ex vivo and in vivo assessment.
Autorzy:
Shrivastava P; Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya, Sagar, MP, India.
Gautam L; Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya, Sagar, MP, India.
Sharma R; Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya, Sagar, MP, India.
Dube D; Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya, Sagar, MP, India.
Vyas S; Bundelkhand Medical College and Hospital, Sagar, MP, India.
Vyas SP; Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya, Sagar, MP, India.
Pokaż więcej
Źródło:
Journal of microencapsulation [J Microencapsul] 2021 Mar; Vol. 38 (2), pp. 108-123. Date of Electronic Publication: 2020 Dec 08.
Typ publikacji:
Journal Article
MeSH Terms:
Antitubercular Agents/*administration & dosage
Isoniazid/*administration & dosage
Macrophages, Alveolar/*microbiology
Mycobacterium tuberculosis/*drug effects
Rifampin/*administration & dosage
Tuberculosis/*drug therapy
Animals ; Antitubercular Agents/pharmacokinetics ; Antitubercular Agents/therapeutic use ; Cell Line ; Drug Delivery Systems ; Humans ; Isoniazid/pharmacokinetics ; Isoniazid/therapeutic use ; Liposomes ; Macrophages, Alveolar/metabolism ; Mice, Inbred BALB C ; Rifampin/pharmacokinetics ; Rifampin/therapeutic use ; Tissue Distribution ; Tuberculosis/metabolism ; Tuberculosis/microbiology
Czasopismo naukowe
Tytuł:
An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study.
Autorzy:
Surey J; Institute for Global Health, University College London, London, UK. .; Faculty of Medicine, Universidad Autónoma Madrid, Madrid, Spain. .
Stagg HR; Usher Institute, University of Edinburgh, Edinburgh, UK.
Yates TA; Institute for Global Health, University College London, London, UK.; Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, W2 1NY, UK.
Lipman M; UCL-TB and UCL Respiratory, UCL, London, Royal Free London National Health Service Foundation Trust, London, UK.
White PJ; National Infection Service, Public Health, England, UK.; Department of Infectious Disease Epidemiology, Imperial College School of Public Health, MRC Centre for Global Infectious Disease Analysis and NIHR Health Protection Research Unit in Modelling Methodology, London, UK.
Charlett A; National Infection Service, Public Health, England, UK.
Muñoz L; Clinical Sciences Department. School of Medicine, University of Barcelona and Internal Medicine Department, Parc Sanitari Sant Joan de Déu. Sant Boi, Barcelona, Spain.
Gosce L; Institute for Global Health, University College London, London, UK.
Rangaka MX; Institute for Global Health, University College London, London, UK.
Francis M; Institute for Global Health, University College London, London, UK.
Hack V; Institute for Global Health, University College London, London, UK.
Kunst H; Blizard Institute, Queen Mary University of London, London, UK.; Department of Respiratory Medicine, Barts Health NHS Trust, London, UK.
Abubakar I; Institute for Global Health, University College London, London, UK.
Pokaż więcej
Źródło:
BMC infectious diseases [BMC Infect Dis] 2021 Jan 21; Vol. 21 (1), pp. 90. Date of Electronic Publication: 2021 Jan 21.
Typ publikacji:
Equivalence Trial; Journal Article; Randomized Controlled Trial
MeSH Terms:
Antitubercular Agents/*therapeutic use
Latent Tuberculosis/*drug therapy
Rifampin/*analogs & derivatives
Rifampin/*therapeutic use
Adolescent ; Adult ; Antitubercular Agents/administration & dosage ; Antitubercular Agents/adverse effects ; Drug Administration Schedule ; Drug Therapy, Combination ; Female ; Humans ; Isoniazid/administration & dosage ; Isoniazid/adverse effects ; Isoniazid/therapeutic use ; London ; Male ; Middle Aged ; Pilot Projects ; Rifampin/administration & dosage ; Rifampin/adverse effects ; Self Administration ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł:
Rifampin-resistant/multidrug-resistant Tuberculosis in Alberta, Canada: Epidemiology and treatment outcomes in a low-incidence setting.
Autorzy:
Edwards BD; Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
Edwards J; Pharmacy Services, Alberta Health Services, Calgary, Alberta, Canada.
Cooper R; Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Kunimoto D; Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Somayaji R; Department of Medicine, University of Calgary, Calgary, Alberta, Canada.; Department of Microbiology, Immunology, and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada.; Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
Fisher D; Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2021 Feb 16; Vol. 16 (2), pp. e0246993. Date of Electronic Publication: 2021 Feb 16 (Print Publication: 2021).
Typ publikacji:
Journal Article
MeSH Terms:
Antitubercular Agents/*pharmacology
Rifampin/*pharmacology
Tuberculosis, Multidrug-Resistant/*drug therapy
Tuberculosis, Multidrug-Resistant/*epidemiology
Adult ; Alberta/epidemiology ; Antitubercular Agents/therapeutic use ; Emigration and Immigration/statistics & numerical data ; Female ; Humans ; Incidence ; Male ; Middle Aged ; Retrospective Studies ; Rifampin/therapeutic use ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł:
Discovery of a highly potent novel rifampicin analog by preparing a hybrid of the precursors of the antibiotic drugs rifampicin and clofazimine.
Autorzy:
Saravanan P; ICMR-National Institute for Research in Tuberculosis, Chennai, India. .
Dusthackeer VNA; ICMR-National Institute for Research in Tuberculosis, Chennai, India.
Rajmani RS; Centre for Infectious Disease and Research, Indian Institute of Science, Bangalore, India.
Mahizhaveni B; ICMR-National Institute for Research in Tuberculosis, Chennai, India.
Nirmal CR; ICMR-National Institute for Research in Tuberculosis, Chennai, India.
Rajadas SE; ICMR-National Institute for Research in Tuberculosis, Chennai, India.
Bhardwaj N; Centre for Infectious Disease and Research, Indian Institute of Science, Bangalore, India.
Ponnuraja C; ICMR-National Institute for Research in Tuberculosis, Chennai, India.
Bhaskar A; ICMR-National Institute for Research in Tuberculosis, Chennai, India.
Hemanthkumar AK; ICMR-National Institute for Research in Tuberculosis, Chennai, India.
Ramachandran G; ICMR-National Institute for Research in Tuberculosis, Chennai, India.
Tripathy SP; ICMR-National Institute for Research in Tuberculosis, Chennai, India. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2021 Jan 13; Vol. 11 (1), pp. 1029. Date of Electronic Publication: 2021 Jan 13.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antitubercular Agents/*chemical synthesis
Clofazimine/*analogs & derivatives
Mycobacterium tuberculosis/*drug effects
Rifampin/*analogs & derivatives
Antitubercular Agents/chemistry ; Bacterial Proteins/antagonists & inhibitors ; Bacterial Proteins/chemistry ; Clofazimine/chemical synthesis ; Clofazimine/chemistry ; DNA-Directed RNA Polymerases/antagonists & inhibitors ; DNA-Directed RNA Polymerases/chemistry ; Drug Design ; Drug Discovery ; Humans ; Magnetic Resonance Spectroscopy ; Mass Spectrometry ; Microbial Sensitivity Tests ; Models, Molecular ; Molecular Docking Simulation ; Molecular Structure ; Monocytes/drug effects ; Mycobacterium tuberculosis/enzymology ; Rifampin/chemical synthesis ; Rifampin/chemistry ; THP-1 Cells
Czasopismo naukowe
Tytuł:
Rifapentine and isoniazid for prevention of tuberculosis in people with diabetes (PROTID): protocol for a randomised controlled trial.
Autorzy:
Ntinginya NE; National Institute for Medical Research (NIMR), Mbeya Medical Research Centre, Mbeya, Tanzania. .
Te Brake L; Departmentt of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center (RUMC), Nijmegen, The Netherlands.
Sabi I; National Institute for Medical Research (NIMR), Mbeya Medical Research Centre, Mbeya, Tanzania.
Chamba N; The Good Samaritan Foundation (Kilimanjaro Christian Medical Centre GSF KCMC), Moshi, Tanzania.; Kilimanjaro Christian Medical University College, Moshi, Tanzania.
Kilonzo K; The Good Samaritan Foundation (Kilimanjaro Christian Medical Centre GSF KCMC), Moshi, Tanzania.; Kilimanjaro Christian Medical University College, Moshi, Tanzania.
Laizer S; The Good Samaritan Foundation (Kilimanjaro Christian Medical Centre GSF KCMC), Moshi, Tanzania.; Kilimanjaro Christian Medical University College, Moshi, Tanzania.
Andia-Biraro I; Department of Internal Medicine, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.
Kibirige D; Uganda Martyrs Hospital Lubaga, Kampala, Uganda.
Kyazze AP; Department of Internal Medicine, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.
Ninsiima S; Department of Internal Medicine, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.
Critchley JA; St George's University of London, London, UK.
Romeo R; King's College London, London, UK.
van de Maat J; Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
Olomi W; National Institute for Medical Research (NIMR), Mbeya Medical Research Centre, Mbeya, Tanzania.
Mrema L; National Institute for Medical Research (NIMR), Mbeya Medical Research Centre, Mbeya, Tanzania.
Magombola D; National Institute for Medical Research (NIMR), Mbeya Medical Research Centre, Mbeya, Tanzania.
Mwayula IH; Mbeya Zonal Referral Hospital (MZRH), Mbeya, Tanzania.
Sharples K; Otago Global Health Institute, University of Otago, Dunedin, New Zealand.
Hill PC; Otago Global Health Institute, University of Otago, Dunedin, New Zealand.
van Crevel R; Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Pokaż więcej
Corporate Authors:
PROTID Consortium
Źródło:
Trials [Trials] 2022 Jun 10; Vol. 23 (1), pp. 480. Date of Electronic Publication: 2022 Jun 10.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Diabetes Mellitus, Type 2*/epidemiology
Isoniazid*/adverse effects
Latent Tuberculosis*/prevention & control
Rifampin*/adverse effects
Rifampin*/analogs & derivatives
Adult ; Antitubercular Agents/adverse effects ; Cohort Studies ; HIV Infections/epidemiology ; Humans ; Randomized Controlled Trials as Topic ; Tanzania/epidemiology
Czasopismo naukowe
Tytuł:
Keeping up with the guidelines: design changes to the STREAM stage 2 randomised controlled non-inferiority trial for rifampicin-resistant tuberculosis.
Autorzy:
Goodall RL; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, 90 High Holborn 2nd Floor, London, WC1V 6LJ, UK. .
Sanders K; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, 90 High Holborn 2nd Floor, London, WC1V 6LJ, UK.
Bronson G; Research Division, Vital Strategies, New York, USA.
Gurumurthy M; Vital Strategies, Singapore, Singapore.
Torrea G; Institute of Tropical Medicine, Antwerp, Belgium.
Meredith S; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, 90 High Holborn 2nd Floor, London, WC1V 6LJ, UK.
Nunn A; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, 90 High Holborn 2nd Floor, London, WC1V 6LJ, UK.
Rusen ID; Research Division, Vital Strategies, New York, USA.
Pokaż więcej
Corporate Authors:
STREAM Trial Team
Źródło:
Trials [Trials] 2022 Jun 07; Vol. 23 (1), pp. 474. Date of Electronic Publication: 2022 Jun 07.
Typ publikacji:
Journal Article
MeSH Terms:
Rifampin*/adverse effects
Tuberculosis, Multidrug-Resistant*/diagnosis
Tuberculosis, Multidrug-Resistant*/drug therapy
Antitubercular Agents/adverse effects ; Clinical Protocols ; Equivalence Trials as Topic ; Humans ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Tytuł:
High frequency of azole resistant Candida spp. colonization among presumptive multidrug resistant tuberculosis (MDR-TB) patients.
Autorzy:
Darma S; Department of Microbiology, Faculty of Medicine Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.
Ambara A; Department of Microbiology, Faculty of Medicine Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.
Aman AT; Department of Microbiology, Faculty of Medicine Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.
Annisa L; Department of Microbiology, Faculty of Medicine Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.
Nurrokhman; Department of Microbiology, Faculty of Medicine Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.
Nuryastuti T; Department of Microbiology, Faculty of Medicine Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.
Wibawa T; Department of Microbiology, Faculty of Medicine Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2020 Nov 19; Vol. 15 (11), pp. e0242542. Date of Electronic Publication: 2020 Nov 19 (Print Publication: 2020).
Typ publikacji:
Comparative Study; Journal Article; Observational Study
MeSH Terms:
Drug Resistance, Multiple, Fungal*
Antifungal Agents/*pharmacology
Antitubercular Agents/*pharmacology
Candida/*drug effects
Candidiasis/*complications
Fluconazole/*pharmacology
Rifampin/*pharmacology
Tuberculosis, Multidrug-Resistant/*complications
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antitubercular Agents/therapeutic use ; Candidiasis/drug therapy ; Candidiasis/microbiology ; Child ; Drug Interactions ; Female ; Humans ; Itraconazole/pharmacology ; Ketoconazole/pharmacology ; Male ; Microbial Sensitivity Tests ; Middle Aged ; Rifampin/therapeutic use ; Species Specificity ; Tuberculosis, Multidrug-Resistant/drug therapy ; Young Adult
Czasopismo naukowe
Tytuł:
Investigation of the efficacy of the short regimen for rifampicin-resistant TB from the STREAM trial.
Autorzy:
Phillips PPJ; UCSF Center for Tuberculosis, University of California San Francisco, San Francisco, USA. .
Van Deun A; Leuven, Belgium.
Ahmed S; MRC Clinical Trials Unit at UCL, London, UK.
Goodall RL; MRC Clinical Trials Unit at UCL, London, UK.
Meredith SK; MRC Clinical Trials Unit at UCL, London, UK.
Conradie F; Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
Chiang CY; Division of Pulmonary Medicine, Department of Internal Medicine, Wanfang Hospital, Taipei Medical University, Taipei, Taiwan.; Division of Pulmonary Medicine, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.; International Union against Tuberculosis and Lung Disease (the Union), Paris, France.
Rusen ID; Research Division, Vital Strategies, New York, USA.
Nunn AJ; MRC Clinical Trials Unit at UCL, London, UK.
Pokaż więcej
Źródło:
BMC medicine [BMC Med] 2020 Nov 04; Vol. 18 (1), pp. 314. Date of Electronic Publication: 2020 Nov 04.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms:
Antitubercular Agents/*therapeutic use
Rifampin/*therapeutic use
Tuberculosis, Multidrug-Resistant/*drug therapy
Antitubercular Agents/pharmacology ; Humans ; Rifampin/pharmacology ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Mixed lichenoid and psoriasiform drug eruption induced by rifampicin.
Autorzy:
Feng X; Department of Dermatology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Ye X; Department of Dermatology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Xu J; Department of Dermatology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Li C; Department of Dermatology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Pokaż więcej
Źródło:
The Australasian journal of dermatology [Australas J Dermatol] 2020 May; Vol. 61 (2), pp. e231-e233. Date of Electronic Publication: 2019 Dec 15.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Antitubercular Agents/*adverse effects
Drug Eruptions/*etiology
Lichenoid Eruptions/*chemically induced
Psoriasis/*chemically induced
Rifampin/*adverse effects
Antitubercular Agents/administration & dosage ; Drug Eruptions/drug therapy ; Humans ; Lichenoid Eruptions/drug therapy ; Psoriasis/drug therapy ; Rifampin/administration & dosage
Czasopismo naukowe
Tytuł:
Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial.
Autorzy:
Semitala FC; Makerere University, Department of Medicine, College of Health Sciences, Kampala, Uganda.; Infectious Diseases Research Collaboration, Kampala, Uganda.; Makerere University Joint AIDS Program, Kampala, Uganda.
Kadota JL; UCSF Center for Tuberculosis and Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America.
Musinguzi A; Infectious Diseases Research Collaboration, Kampala, Uganda.
Nabunje J; Infectious Diseases Research Collaboration, Kampala, Uganda.
Welishe F; Infectious Diseases Research Collaboration, Kampala, Uganda.
Nakitende A; Infectious Diseases Research Collaboration, Kampala, Uganda.
Akello L; Infectious Diseases Research Collaboration, Kampala, Uganda.
Bishop O; Infectious Diseases Research Collaboration, Kampala, Uganda.
Patel D; The Better Lab, Department of Surgery, University of California, San Francisco, San Francisco, California, United States of America.
Sammann A; The Better Lab, Department of Surgery, University of California, San Francisco, San Francisco, California, United States of America.
Nahid P; UCSF Center for Tuberculosis and Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America.
Belknap R; Denver Health and Hospital Authority and Division of Infectious Diseases, Department of Medicine, University of Colorado, Denver, Colorado, United States of America.
Kamya MR; Makerere University, Department of Medicine, College of Health Sciences, Kampala, Uganda.; Infectious Diseases Research Collaboration, Kampala, Uganda.
Handley MA; Center for Vulnerable Populations at Zuckerberg San Francisco General Hospital and Trauma Center, University of California, San Francisco, San Francisco, California, United States of America.; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, United States of America.
Phillips PPJ; UCSF Center for Tuberculosis and Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America.
Katahoire A; Child Health and Development Center, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.
Berger CA; UCSF Center for Tuberculosis and Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America.
Kiwanuka N; Clinical Epidemiology & Biostatistics Unit, Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.
Katamba A; Clinical Epidemiology & Biostatistics Unit, Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.; Uganda Tuberculosis Implementation Research Consortium, Kampala, Uganda.
Dowdy DW; Uganda Tuberculosis Implementation Research Consortium, Kampala, Uganda.; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
Cattamanchi A; UCSF Center for Tuberculosis and Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America.; Uganda Tuberculosis Implementation Research Consortium, Kampala, Uganda.
Pokaż więcej
Źródło:
PLoS medicine [PLoS Med] 2021 Dec 16; Vol. 18 (12), pp. e1003875. Date of Electronic Publication: 2021 Dec 16 (Print Publication: 2021).
Typ publikacji:
Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
MeSH Terms:
Directly Observed Therapy*/classification
Antitubercular Agents/*therapeutic use
Isoniazid/*therapeutic use
Rifampin/*analogs & derivatives
Tuberculosis/*prevention & control
Adult ; Drug Therapy, Combination ; Female ; HIV Infections/etiology ; Humans ; Male ; Middle Aged ; Rifampin/therapeutic use ; Uganda
Czasopismo naukowe
Tytuł:
High rate of successful treatment outcomes among childhood rifampicin/multidrug-resistant tuberculosis in Pakistan: a multicentre retrospective observational analysis.
Autorzy:
Naz F; Department of Pharmacy Practice, Faculty of Pharmacy and Health Sciences, University of Balochistan, Quetta, Pakistan.
Ahmad N; Department of Pharmacy Practice, Faculty of Pharmacy and Health Sciences, University of Balochistan, Quetta, Pakistan. .
Wahid A; Department of Pharmacy Practice, Faculty of Pharmacy and Health Sciences, University of Balochistan, Quetta, Pakistan.
Ahmad I; Department of Biology, Syed Babar Ali School of Science and Engineering, Lahore University of Management Sciences, Lahore, Pakistan.
Khan A; Department of Pharmacy Practice, Faculty of Pharmacy and Health Sciences, University of Balochistan, Quetta, Pakistan.
Abubakar M; Department of Pharmacy Practice, Faculty of Pharmacy and Health Sciences, University of Balochistan, Quetta, Pakistan.
Khan SA; Pakistan Centre of Excellence in Vaccinology & Biotechnology, University of Balochistan, Quetta, Pakistan.
Khan A; Department of Pharmacy, Quaid-i-Azam University, Islamabad, Pakistan.
Latif A; National TB Control Program, Islamabad, Pakistan.
Ghafoor A; National TB Control Program, Islamabad, Pakistan.
Pokaż więcej
Źródło:
BMC infectious diseases [BMC Infect Dis] 2021 Dec 04; Vol. 21 (1), pp. 1209. Date of Electronic Publication: 2021 Dec 04.
Typ publikacji:
Journal Article; Multicenter Study; Observational Study
MeSH Terms:
Rifampin*/therapeutic use
Tuberculosis, Multidrug-Resistant*/drug therapy
Tuberculosis, Multidrug-Resistant*/epidemiology
Adolescent ; Antitubercular Agents/therapeutic use ; Child ; Female ; Humans ; Pakistan/epidemiology ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies